Change over period: —
NSE · ZIMLAB
ZIMLAB
-11.2% from the 52-week high · +124.8% above the low
Zim Laboratories Ltd. is a pharmaceutical company. The company is headquartered in Nagpur, Maharashtra and currently employs 525 full-time employees. The company went IPO on 2018-06-08. The firm develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. The company is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.
The short version. ZIMLAB reported revenue of ₹105 crore for Sep 2026, up 18.0% from a year earlier. Return on equity was 2.0% in Mar 2026. Promoter holding was 30.3% in Sep 2026, down 2.96 points over 8 quarters.
1 · The price
How has the stock traded?
ZIMLAB trades 11.2% below its 52-week high and 124.8% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹105 cr.
1.4 pts lower than a year earlier.
Revenue compounded at -1.6% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 105 | 94 | 105 | 109 | 89 | 72 | 109 | 96 |
| Net profit | -2 | -4 | 4 | 4 | 0 | -2 | 5 | 4 |
| Net margin % | -1.9 | -4.3 | 3.6 | 4.0 | -0.5 | -2.6 | 4.5 | 4.2 |
| EPS (₹) | -0.38 | -0.75 | 0.7 | 0.9 | -0.09 | -0.38 | 1.0 | 0.82 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 374 | 379 | 367 | 399 | 333 | 307 | 278 | 335 |
| Net profit | 6 | 12 | 17 | 24 | 15 | 7 | 3 | 15 |
| Net margin % | 1.6 | 3.2 | 4.7 | 6.1 | 4.4 | 2.2 | 1.2 | 4.6 |
| EPS (₹) | 1.09 | 2.5 | 3.54 | 5.01 | 2.99 | 1.41 | 0.68 | 3.17 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 2.0% in Mar 2026; debt to equity is 0.42.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 2.0 | 4.8 | 7.2 | 12.2 |
| Return on capital % | 6.1 | 9.6 | 10.6 | 17.7 |
| EBITDA margin % | 10.7 | 12.9 | 12.5 | 14.4 |
| Net margin % | 1.5 | 3.2 | 4.6 | 6.0 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | -1.6% | 4.5% |
| Profit CAGR | -38.0% | -3.2% |
4 · The owners
Who holds it, and are they adding?
Down 2.96 pts over 8 quarters.
Down 0.04 pts over 8 quarters.
Up 0.95 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 33.26 | 33.26 | 33.26 | 33.26 | 33.26 | 30.35 | 30.36 | 30.3 | -2.96 |
| FII | 0.21 | 0.01 | 0.03 | 0 | 0.02 | 0 | 0.03 | 0.17 | -0.04 |
| DII | 0.24 | 0.24 | 0.24 | 0.24 | 0.2 | 0.07 | 1.33 | 1.19 | +0.95 |
| Public | 66.28 | 66.49 | 66.46 | 66.51 | 66.52 | 69.58 | 68.28 | 68.34 | +2.06 |
Mutual fund holdings · Oct 2026
1 scheme hold this stock
1 the month before.
- TATA INDIA PHARMA & HEALTHCARE FUND0.57% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for ZIMLAB are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about ZIMLAB
What is the ZIMLAB share price?
ZIMLAB (ZIMLAB) last closed at ₹152.54, up 12.6% on the day. Its 52-week range is ₹60.26 to ₹152.63.
What is the market cap of ZIMLAB?
ZIMLAB has a market capitalisation of about ₹742 crore.
How are ZIMLAB's latest results?
ZIMLAB reported revenue of ₹105 crore for Sep 2026, up 18.0% from a year earlier. Return on equity was 2.0% in Mar 2026. Promoter holding was 30.3% in Sep 2026, down 2.96 points over 8 quarters.
Who owns ZIMLAB?
As of Sep 2026, shareholding was: Promoter 30.3%, FII 0.17%, DII 1.19%, Public 68.34%.
How many mutual funds hold ZIMLAB?
1 mutual fund schemes held ZIMLAB in October 2026. That compares with 1 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 22 Dec 2022 · Bonus issue 2:1
- 19 Sep 2019 · Dividend - Rs. 0.5
- 04 Oct 2018 · Bonus issue 1:1
- 03 Sep 2018 · Final Dividend - Rs. 1
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.